Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis

Rheumatology

Volumn 49, Issue 8, 2010, Pages 1550-1558

  Billiau, An D ^a   Loop, Michèle ^a,b   Le, Phu Quoc ^b   Berthet, Françoise ^c   Philippet, Pierre ^d   Kasran, Ahmad ^a   Wouters, Carine H ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Reine Fabiola Children Hospital   (Belgium)

^c CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^d CHC Espérance ^*  (Belgium)

Author keywords

Etanercept; Growth and body composition; IL 6; Juvenile idiopathic arthritis; Osteoprotegerin

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ETANERCEPT; INTERLEUKIN 6; METHOTREXATE; OSTEOPROTEGERIN;

ADD ON THERAPY; ADOLESCENT; ARTICLE; BODY COMPOSITION; BONE DENSITY; BONE GROWTH; BONE MASS; BONE MINERAL; CHILD; DISEASE ACTIVITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GROWTH RATE; HERPES ZOSTER; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LUMBAR SPINE; MALE; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SKIN DISEASE; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; BONE DENSITY; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; FEMALE; GROWTH; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 77954722960     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq123     Document Type: Article

References (36)

1. Cassidy JT, Petty RE. Juvenile rheumatoid arthritis. Textbook of pediatric rheumatology. Philadelphia: W.B Saunders Company, 2001:218-21.
2. Simon D, Fernando C, Czernichow P, Prieur AM. Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. J Rheumatol 2002;29:1296-300.
3. Pepmueller PH, Cassidy JT, Allen SH, Hillman LS. Bone mineralization and bone mineral metabolism in children with juvenile rheumatoid arthritis. Arthritis Rheum 1996;39:746-57.
4. Liem JJ, Rosenberg AM. Growth patterns in juvenile rheumatoid arthritis. Clin Exp Rheumatol 2003;21:663-8.
5. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology 2002;41:1428-35.
6. Lien G, Flato B, Haugen M et al. Frequency of osteopenia in adolescents with early-onset juvenile idiopathic arthritis: a long-term outcome study of one hundred five patients. Arthritis Rheum 2003;48:2214-23.
7. Zak M, Hassager C, Lovell DJ, Nielsen S, Henderson CJ, Pedersen FK. Assessment of bone mineral density in adults with a history of juvenile chronic arthritis: a cross-sectional long-term followup study. Arthritis Rheum 1999;42:790-8.
8. Oen K. Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 2002;16:347-60.
9. Henderson CJ, Specker BL, Sierra RI, Campaigne BN, Lovell DJ. Total-body bone mineral content in non-corticosteroid-treated postpubertal females with juvenile rheumatoid arthritis: frequency of osteopenia and contributing factors. Arthritis Rheum 2000;43:531-40.
10. Mangge H, Schauenstein K. Cytokines in juvenile rheumatoid arthritis (JRA). Cytokine 1998;10:471-80.
11. Wouters CH, Ceuppens JL, Stevens EA. Different circulating lymphocyte profiles in patients with different sub-types of juvenile idiopathic arthritis. Clin Exp Rheumatol 2002;20:239-48.
12. Walsh NC, Gravallese EM. Bone loss in inflammatory arthritis: mechanisms and treatment strategies. Curr Opin Rheumatol 2004;16:419-27.
13. MacRae VE, Farquharson C, Ahmed SF. The pathophysiology of the growth plate in juvenile idiopathic arthritis. Rheumatology 2006;45:11-9.
14. De Benedetti F, Meazza C, Martini A. Role of interleukin-6 in growth failure: an animal model. Horm Res 2002;58(Suppl. 1):24-7.
15. De Benedetti F, Martini A. Cytokines and growth delay during chronic inflammatory diseases in children. Arch Pediatr 1999;6:499-502.
16. De Benedetti F, Alonzi T, Moretta A et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997;99:643-50.
17. Cimaz R. Osteoporosis in childhood rheumatic diseases: prevention and therapy. Best Pract Res Clin Rheumatol 2002;16:397-409.
18. Kievit W, Fransen J, Oerlemans AJ et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007;66:1473-8.
19. Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
20. Lovell DJ, Reiff A, Jones OY et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94.
21. Quartier P, Taupin P, Bourdeaut F et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-101.
22. Charles P, Elliott MJ, Davis D et al. Regulation of cyto-kines, cytokine inhibitors and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
23. Chedeville G, Quartier P, Miranda M, Brauner R, Prieur AM. Improvements in growth parameters in children with juvenile idiopathic arthritis associated with the effect of methotrexate on disease activity. Joint Bone Spine 2005;72:392-6.
24. Schmeling H, Seliger E, Horneff G. Growth reconstitution in juvenile idiopathic arthritis treated with etanercept. Clin Exp Rheumatol 2003;21:779-84.
25. Tynjala P, Lahdenne P, Vahasalo P, Kautiainen H, Honkanen V. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis 2006;65:1044-9.
26. Vojvodich PF, Hansen JB, Andersson U, Savendahl L, Hagelberg S. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis. J Rheumatol 2007;34:2481-5.
27. Wallace CA, Ravelli A, Huang B, Giannini EH. Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. J Rheumatol 2006;33:789-95.
28. Petty RE, Southwood TR, Baum J et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998;25:1991-4.
29. Giannini EH, Lovell DJ, Felson DT. Preliminary core set of outcome variables for use in JRA clinical trials. Arthritis Rheum 1994;37:S428.
30. Joos R, Ruperto N, Wouters C et al. The Belgian-Flemish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001;19:S20-4.
31. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
32. Giannini EH, Brewer EJ, Kuzmina N et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and the Cooperative Children's Study Group. N Engl J Med 1992;326:1043-9.
33. Horneff G, De Bock F, Foeldvari I et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25.
34. Simonini G, Giani T, Stagi S, de Martino M, Falcini F. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis. Rheumatology 2005;44:777-80.
35. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprote-gerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
36. Glantz LH. Conducting research with children: legal and ethical issues. J Am Acad Child Adolesc Psychiatry 1996;35:1283-91.